Global Muscle Invasive Bladder Cancer (MIBC) Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: Astellas Pharma, Cold Genesys, Taris Biomedical - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H1 2016" report to their offering.

The report provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC)
  • The report reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Muscle Invasive Bladder Cancer (MIBC) therapeutics and enlists all their major and minor projects
  • The report assesses Muscle Invasive Bladder Cancer (MIBC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC)

Companies Mentioned:

  • Astellas Pharma Inc.
  • Cold Genesys, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Oncolytics Biotech Inc.
  • Taris Biomedical LLC

For more information visit http://www.researchandmarkets.com/research/mvjt85/muscle_invasive

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716